: Transforming growth factor-B1 (TGF-Bl) appears to play a major role in the development of atherosclerosis. TGF-Bl is expressed in atherosclerotic human arteries and has potent effects on vascular cells. However, it remains controversial whether TGF-B1 causes or protects against atherosclerosis. This application includes a series of investigations, performed in mice, that will elucidate whether TGF-B1 is pro- or anti-atherogenic. The investigations will also identify mechanisms by which TGF-B1 expression is regulated.
Three specific aims are proposed: (1) To determine the mechanisms through which TGF-B1 promotes neointimal growth in uninjured mouse arteries and to identify mechanisms by which TGF-B1 expression is regulated. (2) To determine whether elevations in systemic or arterial wall TGF-Bl accelerate atherogenesis, and to test whether increased TGF-B1 expression alters extracellular matrix and lipid accumulation, vascular cell proliferation, and PAI-1 expression. (3) To test the hypothesis that loss of the type II TGF-B receptor (tgfbr2) in smooth muscle cells, with concomitant loss of TGF-B1 signaling, retards the development of atherosclerosis.
The specific aims will be accomplished using the complementary strategies of in viva gene transfer to the artery wall and germ line manipulations.
In aim 1, increasing TGF-B1 expression in the mouse carotid artery by gene transfer is expected to promote intimal growth. Specific assays will identify the mechanisms by which this growth occurs.
Aims 2 and 3 take complementary approaches of overexpression and loss of function, achieved by germ line manipulation of the TGF-B1 and its specific receptor, tgfbr2.
In aim 2 TGF-B1 expression will be increased either systemically (in plasma) or locally (in the artery wall).
In aim 3, the effects of TGF-B1 on the artery wall will be blocked by disrupting TGF-B1 signaling in smooth muscle cells. In both aims 2 and 3, the effect of the manipulations on the development of atherosclerosis will be measured. The proposed experiments will define the effects of TGF-B1 on the phenotype of normal and atherosclerotic arteries, elucidate the molecular and cellular mechanisms by which these effects are produced, and clarify the mechanisms through which TGF-B1 expression in the artery wall is regulated. The results of these investigations will reveal whether strategies aimed at blocking the actions of TGF-B1 on the artery wall represent promising approaches to the prevention and treatment of atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL069063-02
Application #
6538103
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Program Officer
Goldman, Stephen
Project Start
2001-07-01
Project End
2006-04-30
Budget Start
2002-05-01
Budget End
2003-04-30
Support Year
2
Fiscal Year
2002
Total Cost
$426,257
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Frutkin, Andrew D; Otsuka, Goro; Stempien-Otero, April et al. (2009) TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 29:1251-7
Frutkin, Andrew D; Shi, Haikun; Otsuka, Goro et al. (2007) Targeted rearrangement of floxed alleles in smooth muscle cells in vivo. Circ Res 101:e124-5
Otsuka, Goro; Stempien-Otero, April; Frutkin, Andrew D et al. (2007) Mechanisms of TGF-beta1-induced intimal growth: plasminogen-independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. Circ Res 100:1300-7
Lee, Sunyoung; Agah, Ramtin; Xiao, Ming et al. (2006) In vivo expression of a conditional TGF-beta1 transgene: no evidence for TGF-beta1 transgene expression in SM22alpha-tTA transgenic mice. J Mol Cell Cardiol 40:148-56
Frutkin, Andrew D; Shi, Haikun; Otsuka, Goro et al. (2006) A critical developmental role for tgfbr2 in myogenic cell lineages is revealed in mice expressing SM22-Cre, not SMMHC-Cre. J Mol Cell Cardiol 41:724-31
Woodward, Robert N; Finn, Aloke V; Dichek, David A (2006) Identification of intracellular pathways through which TGF-beta1 upregulates PAI-1 expression in endothelial cells. Atherosclerosis 186:92-100
Otsuka, Goro; Agah, Ramtin; Frutkin, Andrew D et al. (2006) Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 26:737-43
Lee, Sunyoung; Agah, Ramtin; Xiao, Ming et al. (2005) Regulated transgene expression in vascular smooth muscle. Circ Res 97:e85; author reply e85-7
Cozen, Aaron E; Moriwaki, Hideaki; Kremen, Michal et al. (2004) Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 109:2129-35
Moriwaki, Hideaki; Stempien-Otero, April; Kremen, Michal et al. (2004) Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95:637-44